Related Experiment Video
Updated: May 11, 2025
05:19
Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors
Published on: March 29, 2019
10.3K
Differential Outcomes in Bladder Cancer After Neoadjuvant Chemotherapy: An International Multi-Institutional Study
Andres M Acosta1, Mohammed Saad1, Alcides Chaux2
1Department of Pathology, Indiana University School of Medicine, Indianapolis, IN.
Urology
|April 18, 2025
Summary
Patients with residual lymph node disease after neoadjuvant chemotherapy (NAC) have a higher risk of recurrence but similar survival rates compared to those with persistent muscle-invasive disease. Risk-adapted surveillance is recommended.
Area of Science:
- Oncology
- Urologic Oncology
- Chemotherapy Research
Background:
- Neoadjuvant chemotherapy (NAC) is a standard treatment for muscle-invasive bladder cancer.
- Assessing residual disease patterns after NAC is crucial for predicting patient outcomes.
- Lymph node involvement post-NAC requires careful evaluation for treatment stratification.
Purpose of the Study:
- To evaluate clinical outcomes based on residual disease patterns after NAC and radical cystectomy.
- To specifically investigate outcomes in patients with isolated lymph node disease versus persistent local disease.
Main Methods:
- Retrospective analysis of 174 patients undergoing radical cystectomy post-NAC (2010-2023).
- Stratification into two groups: isolated lymph node disease (n=35) and persistent muscle-invasive/locally advanced disease without nodal involvement (n=139).
- Primary outcomes assessed: recurrence, disease-specific mortality (DSM), and survival, with a median follow-up of 27 months.
Main Results:
- Higher recurrence risk observed in patients with isolated lymph node disease (OR: 0.43, P=.036).
- No significant difference in disease-specific mortality (DSM) between the groups (OR: 0.70, P=.407).
- Lower risk of disease-related events in patients with residual bladder disease (OR: 0.46, P=.048).
Conclusions:
- Isolated lymph node disease post-NAC is associated with increased recurrence risk but not decreased survival.
- Findings support the need for tailored surveillance strategies for patients with residual nodal disease.
- Consideration of additional therapeutic interventions may be warranted for this patient subgroup.
